Aquestive Therapeutics misses Q3 revenue, beats adjusted EBITDA estimates

Aquestive Therapeutics

05/11/2025 21:34

Overview

Aquestive Q3 revenue misses analyst expectations, but adjusted EBITDA beats estimates

Company prepares for potential U.S. launch of Anaphylm in Q1 2026, pending FDA approval

Aquestive strengthens balance sheet to support Anaphylm launch

Outlook

Company expects FY revenue of $44 mln to $50 mln

Aquestive expects FY adjusted EBITDA loss of $47 mln to $51 mln

Company expects to submit IND for AQST-108 in Q4 2025

Result Drivers

MANUFACTURING REVENUE - Increased to $11.5 mln from $10.7 mln due to increases in Sympazan and Suboxone revenues

PATENT EXPANSION - Co broadened Anaphylm patent estate with two new patents extending protection into 2037

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$12.81 mln
$12.94 mln (10 Analysts)
Q3 Net Income
-$15.45 mln
Q3 Adjusted EBITDA
Beat
-$8.56 mln
-$10.72 mln (4 Analysts)
Q3 Income From Operations
-$11.48 mln
Q3 Pretax Profit
-$15.45 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $8.00, about 24% above its November 4 closing price of $6.08

Press Release: ID:nGNX9Nl0fF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)